← Back to Search

FlowSense for Hydrocephalus

N/A
Waitlist Available
Research Sponsored by Rhaeos, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 1 hour
Awards & highlights

Summary

This study compares the performance of two generations of non-invasive cerebrospinal fluid (CSF) shunt flow assessment devices. Measurements of functional implanted shunts and off-shunt locations will assess the diagnostic non-inferiority of the second-generation device to the first-generation device.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 1 hour
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 1 hour for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Study Device Sensitivity
Study Device Specificity

Trial Design

1Treatment groups
Experimental Treatment
Group I: FlowSenseExperimental Treatment1 Intervention
This study compares the performance of two generations of non-invasive cerebrospinal fluid (CSF) shunt flow assessment devices. Measurements of functional implanted shunts and off-shunt locations will assess the diagnostic non-inferiority of the second-generation device to the first-generation device.

Find a Location

Who is running the clinical trial?

Rhaeos, Inc.Lead Sponsor
9 Previous Clinical Trials
616 Total Patients Enrolled
9 Trials studying Hydrocephalus
616 Patients Enrolled for Hydrocephalus
~24 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top